< Back to previous page
Researcher
Isabelle Huys
- Disciplines:Biomarker discovery and evaluation, Drug discovery and development, Medicinal products, Pharmaceutics, Pharmacognosy and phytochemistry, Pharmacology, Pharmacotherapy, Toxicology and toxinology, Other pharmaceutical sciences
Affiliations
- Clinical Pharmacology and Pharmacotherapy (Division)
Responsible
From17 Dec 2020 → Today - Faculty of Law and Criminology (Faculty)
Member
From1 Oct 2014 → 30 Sep 2015 - Clinical Pharmacology and Pharmacotherapy (Division)
Member
From1 Jul 2013 → Today - Toxicology and Pharmacology (Division)
Member
From1 Oct 1999 → 9 Mar 2004
Projects
1 - 10 of 54
- Increasing ATMP regulatory awareness in producers and ATMP acceptance in patients and healthcare professionalsFrom23 Jul 2024 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Regulatory aspects of clinical research not covered by overarching European legislationFrom11 Jun 2024 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Optimising the clinical research framework for cancer treatmentsFrom10 May 2024 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Collaborative licensing models for marine genetic resources in striving for efficient, accessible and equitable management of intellectual property rightsFrom12 Feb 2024 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- How to create sustainable market access to advanced therapies?From1 Jan 2024 → TodayFunding: FWO research project (including WEAVE projects)
- Organoid technologies for disease modeling, drug discovery and development for rare diseasesFrom1 Jan 2024 → TodayFunding: HORIZON.1.2 - Marie Skłodowska-Curie-actions (MSCA)
- Sustainable COVID-19 Vaccination for Long-term Vaccine Immunity and EffectivenessFrom1 Jan 2024 → TodayFunding: HORIZON.2.1 - Health
- Does patient empowerment foster access to and re-use of data in biomedical research, while allowing for meaningful protection of the fundamental right to data protection of patients?From1 Nov 2023 → TodayFunding: FWO junior postdoctoral fellowship
- What are the key factors needed for potential valorization of Marine Natural Products (MNPs)?From1 Nov 2023 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Stakeholder Perspectives on Gene Therapy in CardiomyopathyFrom1 Oct 2023 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
Publications
1 - 10 of 212
- Can Endangered Biosimilar Markets be Rescued? The Need to Bridge Competing Interests for Long-Term Gain(2024)
Authors: Isabelle Huys, Steven Simoens
Pages: 325 - 329 - Patients’ knowledge, preferences, and perspectives about data protection and data control: an exploratory survey(2024)
Authors: Teodora Lalova-Spinks, Isabelle Huys
- Comparing Discrete Choice Experiment with Swing Weighting to Estimate Attribute Relative Importance: A Case Study in Lung Cancer Patient Preferences(2024)
Authors: Rosanne Janssens, Isabelle Huys
Pages: 203 - 216 - Personalized and longitudinal electronic informed consent in clinical trials: How to move the needle?(2024)
Authors: Liese Barbier, Pascal Borry, David Geerts, Isabelle Huys
- Testing and Practical Implementation of a User-Friendly Personalized and Long-Term Electronic Informed Consent Prototype in Clinical Research: Mixed Methods Study(2023)
Authors: David Geerts, Koen Yskout, Stef Verreydt, Pascal Borry, Liese Barbier, Isabelle Huys
- Unlocking Biosimilar Benefits: An Exploration of Barriers to Biosimilar Adoption, Value Assessment and Market Sustainability(2023)
Authors: Teresa Barcina Lacosta, Steven Simoens, Isabelle Huys
- A Belgian policy framework for best-value biological medicines(2023)
Authors: Yannick Vandenplas, Isabelle Huys, Steven Simoens, Arnold Vulto
- Balancing Innovation With Optimization in Oncology: Avenues for Bridging the Cancer Clinical Research Gap(2023)
Authors: Robbe Saesen, Isabelle Huys
- Cross-border clinical research in the EU: Fair allocation of data control and responsibility(2023)
Authors: Teodora Lalova-Spinks, Isabelle Huys, Peggy Valcke
- How can patient preferences be used and communicated in the regulatory evaluation of medicinal products? Findings and recommendations from IMI PREFER and call to action(2023)
Authors: Rosanne Janssens, Liese Barbier, Elise Schoefs, Isabelle Huys